Brief: Sprint Bioscience Announces Identity Of Target Protein In Project VADA
May 13 (Reuters) - Sprint Bioscience AB SPRINT.ST :
* ANNOUNCES THE IDENTITY OF THE TARGET PROTEIN IN THE
WHOLLY-OWNED
PROJECT VADA
* GOAL IS TO DEVELOP DRUG SUBSTANCES THAT INHIBIT PROTEIN
VACCINIA-RELATED KINASE 1 (VRK1) IN ORDER TO ENHANCE EFFECTS OF
IMMUNO-ONCOLOGY THERAPY, RADIATION THERAPY AND CHEMOTHERAPY
Source text for Eikon: ID:nWkr5rtlz2
Further company coverage: SPRINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln